Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Preliminary Phase Ib/II Data supports the controllable Safety and encouraging Efficacy in Patients with relapsed/refractory (R/R) diffuse large B-Cell Lymphoma (DLBCL)

被引：0
|
作者：
Hutchings, M. [1 ]
Sureda, A. [2 ]
Terol, M. J. [3 ]
Bosch, F. [4 ]
Corradini, P. [5 ,6 ]
Stauffer, Larsen T. [7 ]
Rueda, Dominguez A. [8 ]
Panchal, A. [9 ]
Bottos, A. [10 ]
Carlile, D.
Wang, Y. [11 ]
de L'Etang, Filezac A. [10 ]
Tandon, M.
Sellam, G. [10 ]
Gritti, G. [12 ]
机构：
[1] Rigshosp, Copenhagen, Denmark
[2] Inst Catala Oncol Hosp, Barcelona, Spain
[3] Univ Valencia, Hosp Clin Univ INCLIVA, Valencia, Spain
[4] Univ Hosp Vall Hebron, Barcelona, Spain
[5] Univ Milan, Milan, Italy
[6] Fondazione IRCCS Ist Nazl Tumori, Milan, Italy
[7] Odense Univ Hosp, Odense, Denmark
[8] Reg & Virgen Victoria Univ Hosp, Malaga, Spain
[9] Roche Prod Ltd, Welwyn Garden City, Herts, England
[10] F Hoffmann Roche Ltd, Basel, Switzerland
[11] F Hoffmann Roche Ltd, Shanghai, Peoples R China
[12] Ospedale Papa Giovanni 23, Bergamo, Italy
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V195
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [31] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Gatwood, Justin
    Masaquel, Anthony
    Ross, Ryan
    Sheinson, Danny
    Hossain, Farah
    Li, Jia
    James, Cameron
    Fox, David
    BLOOD, 2022, 140 : 7906 - 7907
  • [32] Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab Plus Bendamustine in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Single Center Analysis of Pola Compassionate Use Program (CUP) in China
    Yang, Tao
    Li, Jun
    Zhang, Lingqian
    Hu, Renzhi
    Wu, Jing
    Ding, Yao
    Liang, Xiping
    Quan, Xi
    Hu, Chongling
    Zhang, Wenjun
    Guo, Bingling
    Wang, Chaoyu
    Li, Qiying
    Li, Jieping
    Nan, Yingyu
    Xiang, Ying
    Liu, Yao
    BLOOD, 2022, 140 : 12139 - 12139
  • [33] Preliminary Safety and Efficacy of Zanubrutinib in Combination with Lenalidomide in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
    Zhang, Huilai
    Zhou, Keshu
    Cheng, Ying
    Zhang, Liling
    Yang, Haiyan
    Zou, Liqun
    Cao, Junning
    Huang, Huiqiang
    Guo, Ye
    Wang, Zhao
    Huang, Sha
    Liang, Zhiyu
    Yao, Hui
    Guo, Haiyi
    Fang, Yiqian
    Zhu, Hongjie
    BLOOD, 2022, 140 : 3750 - 3751
  • [34] Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase Ib/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Budde, Elizabeth
    Ghosh, Nilanjan
    Chavez, Julio
    Lossos, Izidore S.
    Mehta, Amitkumar
    Dorritie, Kathleen
    Kamdar, Manali
    Negricea, Raluca
    Song Pham
    Hristopoulos, Maria
    Huw, Ling-Yuh
    O'Hear, Carol
    Oki, Yasuhiro
    To, Iris
    Diefenbach, Catherine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S393 - S394
  • [35] Pola-R-ICE: Results of the safety run-in phase of a phase III study comparing polatuzumab vedotin in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) with R-ICE alone in patients with refractory or relapsed diffuse large B-cell lymphoma
    Laube, A.
    Fuhrmann, S.
    Van Heteren, P.
    Ziepert, M.
    Altmann, B.
    Davies, A.
    Greil, R.
    Garcia-Sancho, A. M.
    Gonzalez De Villambrosia Pellon, S.
    Schnetzke, U.
    De la Cruz Vicente, F.
    Haenel, M.
    Hess, G.
    Koehler, C.
    Masius, H.
    Glass, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 83 - 84
  • [36] A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
    Flinn, Ian W.
    Bartlett, Nancy L.
    Blum, Kristie A.
    Ardeshna, Kirit M.
    LaCasce, Ann S.
    Flowers, Christopher R.
    Shustov, Andrei R.
    Thress, Kenneth S.
    Mitchell, Patrick
    Zheng, Fred
    Skolnik, Jeffrey M.
    Friedberg, Jonathan W.
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : 11 - 17
  • [37] Efficacy and Safety of Ibrutinib as Monotherapy or Combination Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): A Systematic Review and Meta-analysis
    Li, Yin
    Li, Chunfan
    Lv, Kebing
    Wang, Shixuan
    Li, Fei
    AMERICAN JOURNAL OF THERAPEUTICS, 2025, 32 (01) : e5 - e16
  • [38] Cost effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (Pola-R-CHP) in previously untreated diffuse large B-cell lymphoma.
    Kambhampati, Swetha
    Saumoy, Monica
    Pak, Stacy
    Budde, L. Elizabeth
    Mei, Matthew Genyeh
    Popplewell, Leslie
    Wen, Yi-Ping
    Forman, Stephen J.
    Kwak, Larry W.
    Rosen, Steven T.
    Herrera, Alex Francisco
    Thiruvengadam, Nikhil
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Efficacy and Safety of Reduced-Dose Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone ( Pola-R-CHP) in Patients over 80 with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
    Miyao, Kotaro
    Wakayama, Tomoyoshi
    Ozaki, Somi
    Numata, Masaya
    Negishi, Shuto
    Ohara, Fumiya
    Motegi, Kenta
    Wakabayashi, Hiroya
    Sawa, Hitomi
    Sakai, Toshiyasu
    Inagaki, Yuichiro
    Sawa, Masashi
    BLOOD, 2023, 142
  • [40] Preliminary Safety and Efficacy Data of Combination Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Adriamycin, Prednisone (Pola-R-CHP) in Patients With Diffuse Large B- Cell Lymphoma (DLBCL) in the Standardof-Care Setting: A Single-Center Experience
    Khadka, Sushmita
    Dong, Ning
    Chavez, Julio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S480 - S480
12345